Loading...
Please wait, while we are loading the content...
Real-world analysis of the use of lenvatinib in differentiated thyroid cancers.
| Content Provider | Europe PMC |
|---|---|
| Author | Peelay, Zoya Parekh, Deevyashali Patil, Vijay M Noronha, Vanita Menon, Nandini Prabhash, Kumar |
| Copyright Year | 2023 |
| Abstract | IntroductionLenvatinib is one of the approved treatments for radioiodine-refractory differentiated thyroid cancers. However, there is very limited data from India on real-world efficacy and adverse events of Lenvatinib and hence this analysis was performed.MethodsThis was a retrospective analysis in which patients of radioiodine-refractory differentiated thyroid cancer as per the SELECT study criteria, who received lenvatinib, were selected for the study over the last 4 years. The baseline demographic characteristics, adverse events of lenvatinib, the date of progression and the date of overall survival (OS) were extracted from the electronic medical records of Tata Memorial Hospital. SPSS version 20 was used for analysis.ResultsThe median starting dose of lenvatinib was 20 mg. Fifteen events for progression had occurred and the median progression-free survival (PFS) was 12.2 months [95% CI: 4.4–not available (NA)]. The events for OS analysis were 12. The median OS was 35.3 months (95% CI: 11.4–NA). There was no impact on starting dose on PFS or OS.ConclusionThe real-world data of Lenvatinib suggest a lot of variability in the starting dose. In spite of this variability, the response rates and OS are similar to that noted in pivotal study. This suggests a case for need for more studies evaluating lower doses of Lenvatinib. |
| Journal | ecancermedicalscience |
| Volume Number | 17 |
| PubMed Central reference number | PMC9937066 |
| PubMed reference number | 36816785 |
| e-ISSN | 17546605 |
| DOI | 10.3332/ecancer.2023.1500 |
| Language | English |
| Publisher | Cancer Intelligence |
| Publisher Date | 2023-01-30 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © the authors; licensee ecancermedicalscience. |
| Subject Keyword | lenvatinib thyroid cancer papillary follicular radioiodine refractory dedifferentiated |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |
